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ABSTRACT 
 
Generic preference-based measures (GPBMs) of health are used to obtain the quality adjustment 
weight required to calculate the quality adjusted life year (QALY) in health economic models.  
GPBMs have been developed to use across different interventions and medical conditions and 
typically consist of a self-complete patient questionnaire, a health state classification system, and 
preference weights for all states defined by the classification system.   
 
Of the six main GPBMs, the three most frequently used are: the HUI3, the EQ-5D (3 and 5 level), and 
the SF-6D.  There are considerable differences in GPBMs in terms of the content and size of 
descriptive system (i.e. the numbers of dimensions of health and levels of severity within these), the 
methods of valuation (e.g. time-trade off (TT0), standard gamble (SG)) and the populations (e.g. 
general population, patients) used to value the health states within the descriptive system.  
Although GPBM are anchored at one (full health) and zero (dead) they produce different health state 
utility values (HSUV) when completed by the same patient. 
 
Considerations when selecting a measure for use in a clinical trial include practicality, reliability, 
validity and responsiveness.  Requirements of reimbursement agencies may impose additional 
restriction on suitable measures for use in economic evaluations such as the valuation technique 
(TTO, SG) or the source of values (general public versus patients).   
 
 
KEY POINTS FOR DECISION MAKERS 
x A generic preference-based measure (GPBM) is a measure of health related quality of life 
that has a set of preference weights that enable a health state utility value (HSUV) to be 
generated for each completion of the measure. 
x Despite being anchored on the same zero (for dead) to one scale (full health), GPBMs 
generate different HSUVs for the same patient and these differences have important 
implications for incremental cost-effectiveness ratios. 
x The selection of a GPBM for any given study should be based on: a) the psychometric 
assessment (content validity, construct validity and responsiveness) in the particular health 
condition, and b) the different jurisdiction requirements for the instrument and methods of 
valuation.  
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1. A REVIEW OF GENERIC PREFERENCE-BASED MEASURES 
Increasingly reimbursement agencies require health care products to be evaluated in terms of their 
cost-effectiveness, where effectiveness is measured in terms of the quality adjusted life year (QALY).  
The purpose of health utility measurement is to provide the quality adjustment weight, in order to 
calculate the QALY in health economics.  Generic preference-based measures (GPBMs) of health 
(also known as multi-attribute utility scales) are commonly used methods for obtaining this weight 
known as a health state utility value (HSUV). 
 
2. What is a generic preference-based measure of health? 
GPBMs ĂƌĞ  ‘ŽĨĨ ƚŚĞ ƐŚĞůĨ ? ŵĞĂƐƵƌĞƐ ƚŚĂƚ ƚǇƉŝĐĂůůǇ ĐŽŶƐŝƐƚ ŽĨ Ă ƐĞůĨ-complete patient standardized 
questionnaire (i.e. a generic multi-attribute utility instrument), a health state classification system 
(i.e. descriptive system), and preference weights for all states defined by the classification system.  
In practice, each patient (or their proxy) completes the questionnaire and their responses are used 
to assign them to a unique health state from the health state classification system.  The utility score 
for the unique health state is then obtained using an existing tariff or value set of preference 
weights. 
 
GPBMs have been developed to be comparable across different interventions and medical 
conditions.  They are accepted by many different agencies around the world concerned with 
assessing the cost-effectiveness of health care including the National Institute for Health and Care 
Excellence (NICE) and others [1].  The self-complete questionnaires used to collect health state data 
can be easily included in clinical trials or routine data collection systems with little respondent 
burden, and the existing scoring algorithms are quickly and easily used to generate the health state 
utility values.   
 
3. Description of the generic preference-based measures 
3.1  Generic multi-attribute utility measures overview 
The number of GPBMs has proliferated over the last two decades.  These include the Quality of Well-
being self-administered (QWB-SA) scale [2], the Health Utilities Index version 3 (HUI3) [3], the EQ-5D 
(3 and 5 level) [4,5], the Short Form 6 dimension (SF-6D) [6,7] and the Assessment of Quality of Life 8 
dimension (AQOL-8D) [8].  Whilst these measures all claim to be generic, in other words they can be 
used in any (adult) patient population across a range of health issues; they differ considerably in 
terms of the content and size of their descriptive system, the methods of valuation and the 
populations used to value the health states (though most use a general population sample).  A 
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summary of the main characteristics of these six measures is presented in Table 1 and Table 2 (see 
[9] for further details).   
 
Table 1 summarises the descriptive content of these measures including their dimensions and 
severity levels.  The original EQ-5D with 3 levels (i.e. EQ-5D-3L) has the smallest classification system, 
defining 243 states and the self-complete EQ-5D-3L questionnaire is reproduced in full in Table 3.  
Recently a new 5-level version of the EQ-5D has been published which covers the same dimensions 
but now generates 3,125 states.  The largest system is the AQOL-8D with 2.37*10
23
 states.  A review 
of articles published on Web of Science (2004-2010) reported that the most widely used multi-
attribute utility (MAU) instrument by far is the EQ-5D, with 63.2% of studies employing a GPBM 
using it, followed by HUI3 (9.8%) and then SF-6D (8.8%) [10].  dŚŝƐ ŚĂƐ ďĞĞŶ ƉĂƌƚůǇ ůĞĚ ďǇ E/ ?Ɛ
preference for EQ-5D ([11] and later replaced by [12]). 
 
The responses given by the patient to the MAU instrument define their health state within the 
ĚĞƐĐƌŝƉƚŝǀĞƐǇƐƚĞŵ ?ƉĞƌƐŽŶŝŶƚŚĞ “ďĞƐƚƉŽƐƐŝďůĞŚĞĂůƚŚ ?ǁŝůůǀĞƌǇůŝŬĞůǇƌĞƉŽƌƚƚŚĞďĞƐƚůĞǀĞů  “ ? ?
across all items within the instrument thus in theory, a pĂƚŝĞŶƚŝŶ “ĨƵůůŚĞĂůƚŚ ?ǁŽƵůĚŚĂǀĞĂŚĞĂůƚŚ
ƐƚĂƚĞŽĨ “ ? ? ? ? ? ?ĨŽƌƚŚĞY-5D-3L.  A hypothetical patient ɲ with impairments in mobility (level 2) 
and in pain/discomfort (level 2) (but no impairment in the other items) would likely report a health 
ƐƚĂƚĞŽĨ “ ? ? ? ? ? ?ĨŽƌƚŚĞY-5D-3L. 
 
3.2  Valuation methods  
The objective of valuing the health states is to provide preference weights for all states defined 
within the classification system.  The resulting set of preference weights enables a HSUV to be 
generated ĨƌŽŵƚŚĞƉĂƚŝĞŶƚ ?ƐƌĞƐƉŽŶƐĞƐƚŽƚŚĞŽƌŝŐŝŶĂůƋƵĞƐƚŝŽŶŶĂŝƌĞ ?dŚĞƌĞĂƌĞƐĞǀĞƌĂůƚĞĐŚŶŝƋƵĞƐ
that can be used to obtain the preference weights and Table 2 summarises the valuation methods 
used in terms of the valuation technique and the method of modelling the valuation data.  The two 
main techniques of valuation have been time trade-off (TTO), where respondents are asked to trade 
life years in the ill health state for a better health state in full health, and standard gamble (SG) 
where respondents are asked the risk of death they are willing to take in order to be in full health 
(for further details see [9]).   More recently, researchers have been using discrete choice 
experiments (DCE) to value health states [13-18], but DCE alone has not been used to provide the 
official tariff for any GPBM though it has been used as a hybrid model with TTO for the recent UK 
valuation of EQ-5D-5L [19].  
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For all instruments a selected subset of health state combinations has been valued by a 
representative sample of the public and then a scoring algorithm has been obtained to estimate 
values for the remaining combinations.  The scoring algorithm is estimated from the health states 
that have been valued.  The main method has been to use statistical regression based approaches, 
where the value of a health state is assumed to be a function of that state; hence, by estimating a 
relationship between the descriptive system and the observed values we can infer values for all 
states.  Most models have been additive, which means they assume no interactions between 
dimensions.  Any model specification should deal with the skewed and truncated nature of the 
distribution of health state values, and the fact that the data are likely to be clustered by 
respondents [20].  Estimation has mainly used generalised least squares (GLS) or maximum 
likelihood estimate (MLE) [9], though more recently alternative techniques for analysing preference 
data have been explored including: Bayesian non-parametric (e.g. SF-6D, [21], semi-parametric 
approaches [22] and a hybrid approach that combines cardinal preference data with the results of 
paired data from a discrete choice experiment (e.g. EQ-5D-5L) [19,23].   The statistical validity of 
models for estimating preference weights are published by the authors, though not independently 
tested..  
 
The multi-attribute utility theory (MAUT), which specifies a functional form in advance and uses the 
values for the levels of each dimension combined with values for corner states to mathematically 
solve the function, has also been used (see [9] for an overview).  MAUT has been explored to allow 
for interactions using a multiplicative form that allows for some highly restrictive forms of 
interaction (e.g. HUI3).  However, evidence suggests statistical approaches are better at predicted 
health state values than MAUT (see [9] for details).  
 
3.2 Valuation surveys 
Valuation surveys have been undertaken across many countries for EQ-5D [24], but rather fewer for 
the others.  For example, Szende et al [25] published value sets for EQ-5D-3L for a range of 
countries.  All measures have an upper-bound health state utility value of 1.0 for full health but 
differ in terms of their lower-bound value ranging from 0.301 (SF-6D [7]) to -0.59 (EQ-5D-3L) when 
using the UK valuations [26].  It is worth noting that some measures include negative utility values 
representing health states that are valued by the general public as being ´worse-than-dead´.  
Worked examples of how to calculate UK EQ-5D-3L HSUVs for patients with differing responses (e.g. 
responses representing the health state  “ ? ? ? ? ? ?ĨŽƌƚŚĞY-5D-3L in England) are provided in Box 1. 
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Table 1 Descriptive systems of GPBMs 
Instrument No. of 
dimensions 
Dimensions No. of 
severity 
levels 
No. of health state combinations 
15D
[67] 
15 Breathing, depression, discomfort/symptoms, 
distress, eating, elimination, hearing, mental 
function, mobility, sexual activity, sleeping, 
speech, usual activities, vision vitality,  
4 W5 31 billion 
AQoL-8D
[8] 
8 Coping (n=3 items), happiness (4), independent 
living (4), mental health (8), pain (3), 
relationship (7), self-worth (3), senses (3)  
4-6 2.37*10
23
 
EQ-5D-3L
[26] 
 
5 Anxiety/depression, mobility, pain/discomfort, 
self-care, usual activities  
3  
 
243   
 
EQ-5D-5L
[5] 
5 Anxiety/depression, mobility, pain/discomfort, 
self-care, usual activities 
5 3,125 
HUI3
[3] 
8 Ambulation, cognition, dexterity, emotion, 
hearing, pain, speech, vision 
5 W6 972,000 
SF-6D
[6]# 
6 Energy, mental health, pain, physical 
functioning, role limitation, social functioning  
4 W6 18,000 (SF-36 v1), 18,750 (SF-36 v2) and 7,500 (SF-
12) 
QWB-SA
[2] 
3 (+68) Mobility, physical activity, social functioning  
68 symptoms/problems 
2 
 
945 
 
#
 SF-6D health state utility values may be obtained from the longer (SF-36) or shorter (SF-12) questionnaire.  Key: 15D  W 15-dimensional; AQoL-8D  W Assessment of quality 
of life 8 dimension; EQ-5D  W Euroqol 5 dimension; HUI3  W Health utility index version 3, SF-6D  W short-form 6 dimension; QWB-SA  W Quality of well-being self-administered 
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Table 2 Valuation methods of GPBMs 
Instrument Country Valuation technique
 
Type of model HSUV range
#
 
(min, max) 
15D
[67] 
Finland VAS MAUT additive 0.11, 1 
AQoL-8D
[8] 
Australia VAS transformed into 
TTO 
MAUT multiplicative and 
statistical 
-0.04, 1 
EQ-5D
[26] 
3L: UK, US plus 16 others  
 
5L: UK plus others 
3L: Ranking, TTO, VAS,  
 
TTO, DCE 
Statistical additive  
 
Statistical additive 
3L UK: -0.59, 1 
 
5L UK: -0.208, 1 
HUI3
[3] 
Canada, France VAS transformed into 
SG 
MAUT multiplicative -0.36, 1 
SF-6D
[6] 
UK and 5 others SG, ranking 
V2: DCE with duration  
Statistical additive with 
interaction term 
0.301, 1 
QWB-SA
[2] 
USA VAS Statistical additive, except for 
symptom/problem complexes 
0.08, 1 
 
# 
Health states are anchored at 1 (full health) and zero (death) with negative values representing health states valued to be worse than death.  Key: 15D  W 15-dimensional; 
AQoL-8D  W Assessment of quality of life 8 dimension; EQ-5D  W Euroqol 5 dimension; HUI3  W Health utility index version 3, SF-6D  W short-form 6 dimension; QWB-SA  W 
Quality of well-being self-administered; VAS  W visual analogue scale; TTO  W  time trade-off;  MAUT  W multi-attribute utility theory; SG  W standard gamble; DCE  W discrete 
choice experiment 
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Table 3 EQ-5D-3L classification 
Dimension Level Description 
Mobility (MOB) 1 I have no problems walking about 
 2 I have some problems walking about 
 3 I am confined to bed 
Self-Care (SC) 1 I have no problems with self-care 
 2 I have some problems washing or dressing myself 
 3 I am unable to wash or dress myself 
Usual activities (UA) 1 I have no problems with performing usual activities
#
 
 2 I have some problems with performing usual activities 
 3 I am unable to perform usual activities 
Pain/discomfort (Pain) 1 I have no pain or discomfort 
 2 I have moderate pain or discomfort 
 3 I have extreme pain or discomfort 
Anxiety/depression (AD) 1 I am not anxious or depressed 
 2 I am moderately anxious or depressed 
 3 I am extremely anxious or depressed 
Source: (Brooks, 1996 [4]).  # e.g. work, study, housework, family or leisure activities
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Box 1 Example of using the EQ-5D-3L tariff for the UK 
 
Worked examples of how to generate a HSUV for responses to the EQ-5D-3L questionnaire using the UK tariff [26]  ൌ  ?D?D?ǡ ǡ ǡ  ?O?Ǥ ǤO? 
otherwise  ൌ  ? െO?O? Ǥ ? ? ?B?  ? ൅  ?Ǥ  ? ?B?  ?O?൅ O? Ǥ ? ? ?B? ? ൅  ?Ǥ ? ? ?B? ?O?൅ O? Ǥ ? ? ?B? ? ൅  ?Ǥ ? ? ?B? ?O?൅ O? Ǥ ? ? ?B?  ? ൅  ?Ǥ  ? ?B?  ?O?൅ O? Ǥ ? ? ?B? ? ൅  ?Ǥ ? ? ?B? ?O?൅ O? Ǥ ? ? ?B?  ? ?O?൅ O? Ǥ ? ? ?B?  ?O?O? 
 
Health dimension Level selected by patient A, B, C and D 
 A B C D 
Mobility (MOB) 1 1 2 3 
Social care (SC) 1 2 2 3 
Usual activities (UA) 1 1 2 3 
Pain 1 2 3 3 
Anxiety/depression (AD) 1 1 2 3 
HSUV generated 
Apply tariff weights If all responses on all 5 
dimensions are 1, then 
HSUV = 1 
 ? െO?O? Ǥ ? ? ?B? ?O?൅O? Ǥ ? ? ?B?  ?O?൅O? Ǥ ? ? ?B?  ?O?O?   ? െO?O? Ǥ ? ? ?B?  ?O?൅O? Ǥ ? ? ?B? ?O?൅O? Ǥ ? ? ?B?  ?O?൅O? Ǥ ? ? ?B? ?O?൅O? Ǥ ? ? ?B?  ? ?O?൅O? Ǥ ? ? ?B?  ?O?O?  
 
 ? െO?O? Ǥ ? ? ?B?  ?O?൅O? Ǥ ? ? ?B? ?O?൅ O? Ǥ ? ? ?B? ?O?൅ O? Ǥ ? ? ?B?  ?O?൅O? Ǥ ? ? ?B?  ? ?O?൅O? Ǥ ? ? ?B?  ?O?O?  
 
HSUV 1 0.796 -0.016 -0.594 
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4. Do different GPBMs produce the same scores? 
All GPBMs are anchored at one for full health and zero ĨŽƌ  ‘ĚĞĂĚ ? ? ďƵƚthis does not imply they 
generate the same values because of the differences in their descriptions of health and the methods 
of valuation.  Indeed there is a substantial body of evidence to show they do not produce the same 
values when administered to the same patients.  A review of 24 studies found that agreement 
between HSUVs (i.e. the utility values) from different GPBMs was generally poor to moderate 
(around 0.3-0.5 as measured by the intra class correlation coefficient) [9].  Whilst aggregate 
differences in mean HSUVs scores in large patient samples obtained from the SF-6D, EQ-5D and HUI3 
have often been found to be little more than 0.05, this statistic (i.e. the mean HSUV) masks 
considerable differences within patient groups, and hence the HSUV estimates for differences and 
changes used to estimate cost-effectiveness used to calculate the mean HSUV.  Some GPBM are 
ƉƌŽŶĞƚŽ ‘ĐĞŝůŝŶŐĞĨĨĞĐƚƐ ?ǁŚĞƌĞďǇĂƐƵďƐƚĂŶƚŝĂůŶƵŵďĞƌŽĨƌĞƐƉŽŶĚĞŶƚƐŝŶĚŝĐĂƚĞƚŚĞǇĂƌĞŝŶƚŚĞďĞƐƚ
possible health state.  The EQ-5D has the largest proportion at the ceiling (i.e. ŚĞĂůƚŚƐƚĂƚĞ P ‘ ? ? ? ? ? ?
and corresponding HSUV: 1.0), followed by HUI3 and 15D.  Important differences have been found 
for specific conditions like vision and hearing [27,28] and large differences were found in the size of 
gain in total hip arthroplasty patients [10].   
 
A recent on-line survey involving six countries (Australia, USA, UK, Norway, Germany, Canada) 
ĐŽŵƉĂƌĞĚƚŚĞƐŝǆŵĂŝŶ'WDƐŝŶĂƐĂŵƉůĞ  ?ŶA?  ? ? ? ? ?ĐŽǀĞƌŝŶŐďŽƚŚ  ‘ŚĞĂůƚŚǇ ?ƌĞƐƉŽŶĚĞŶƚƐĂŶĚ  ? ?
health conditions (asthma, cancer, depression, diabetes, hearing loss, arthritis, heart disease, 
chronic obstructive pulmonary disease, stroke) [10].  When comparing the mean HSUVs for six 
individual conditions with the general population, the mean differences were found to be largest for 
the HUI3, followed by EQ-5D, AQoL, QWB and SF-6D.  Such differences have important implications 
for the cost-effectiveness of interventions.  Ranking by effect sizes (i.e. dividing through by their 
standard deviations) resulted in the QWB having the largest difference between the six diseases and 
the general population, followed by 15D, SF-6D with HUI3 and EQ-5D having the least difference.  
This has implications for sample sizes, since those with larger effect sizes have more power to detect 
a given difference.  For example, the EQ-5D and HUI3 would need to be collected in a much larger 
sample than the QWB or 15D to detect a difference between subgroups defined by condition 
severity.  These differences will increase the uncertainty in the ICER considerably. 
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5. The psychometric properties of the GPBMs 
Patient reported outcome measures are typically evaluated using the psychometric criteria of 
practicality, reliability, validity and responsiveness.  Please refer to Box 2 for a description of the 
criteria to select a GBPM.  All six commonly used generic measures have been shown to be practical, 
though the longer ones raise more concerns about patient burden and achieve lower levels of 
completion (see [10,30] for an overview).  There is no evidence of differences in re-test reliability 
between the generic measures in terms of their ability to re-produce scores in patients who 
complete the scores on two occasions close apart when there has been no change in health.  The 
most contentious area is validity due to the absence of a gold standard measure of health and it is 
very difficult to demonstrate a measure is valid or not, since it is usually a question of degree.  
Traditionally, psychometricians have examined the validity of measures in terms of content validity, 
construct validity, and responsiveness (see Box 2 for definition of terms [31].  
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Table 4 Comparison of the content of six GPBMs  
Domains EƵŵďĞƌŽĨŝƚĞŵƐƌĞƉƌĞƐĞŶƚŝŶŐƚŚĞĚŽŵĂŝŶ 
Physical domains and somatic sensations YŽ> ? ? ? EQ-5D[26] ,h/ ? ? ? ? Yt-^ ? ? ? ^&- ? ? ? ?  ? ? ? ? ? ? 
DŽďŝůŝƚǇ ?ƉŚǇƐŝĐĂůĂĐƚŝǀŝƚǇ 2 1  ?  ?  ?  ? 
ŽĚŝůǇĨƵŶĐƚŝŽŶ ?ƐĞůĨ-ĐĂƌĞ  ? 1  ?  ? ?  ?  ? 
ĞǆƚĞƌŝƚǇ    ?    
WĂŝŶ ?ĚŝƐĐŽŵĨŽƌƚ 2 1  ?  ? ?  ?  ? 
^ĞŶƐĞƐ ?ǀŝƐŝŽŶ ?ŚĞĂƌŝŶŐ ?  ?  2  ?   ? 
hƐƵĂůĂĐƚŝǀŝƚŝĞƐ ?ǁŽƌŬ ?ƌŽůĞ  ? 1   ? ?  ?  ? 
ŽŵŵƵŶŝĐĂƚŝŽŶ  ?   ?  ?   ? 
sŝƚĂůŝƚǇ  ?    ?  ?  ? 
^ůĞĞƉŝŶŐ  ?    ?   ? 
Psychosocial or emotional domains AQoL EQ-5D ,h/ ? Yt-^ ^&- ?  ? ? 
tĞůůďĞŝŶŐ PĚĞƉƌĞƐƐŝŽŶ ?ĂŶǆŝĞƚǇ ?ŚĂƉƉŝŶĞƐƐ ?ĐĂůŵŶĞƐƐ  ?  ?  ?  ?  ?  ? 
,ŽƉĞ  ?    ?   
ƵƚŽŶŽŵǇ ?ĐŽŶƚƌŽů ?ĚŝŐŶŝƚǇ  ?      
^ĞůĨ-ĞƐƚĞĞŵ ?ŝĚĞŶƚŝƚǇ  ?    ?   
DĞĂŶŝŶŐ ?ĂĐŚŝĞǀĞŵĞŶƚ       
^ĂĨĞƚǇ ?ƐĞĐƵƌŝƚǇ       
ŽŐŶŝƚŝŽŶ ?ŵĞŵŽƌǇ    ?  ?   
hƐƵĂůĂĐƚŝǀŝƚŝĞƐ ?ǁŽƌŬ ?ƌŽůĞƌĞůĂƚĞĚƚŽŵĞŶƚĂůŚĞĂůƚŚ  ?  ?   ? ?  ?  
ZĞůĂƚŝŽŶƐŚŝƉƐ ?ƐŽĐŝĂůĨƵŶĐƚŝŽŶŝŶŐ ?ďĞůŽŶŐŝŶŐ  ?    ?   
&ĂŵŝůǇ  ?      
/ŶƚŝŵĂĐǇ ?ŝŶĐůƵĚŝŶŐƐĞǆƵĂůƌĞůĂƚŝŽŶƐ ?  ?    ?   
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5.1  Validity and responsiveness criteria  
Content validity is defined as the extent to which the classification comprehensively covers the 
different dimensions of a health condition and whether it misses important ones.  To be accepted as 
generic, a measure should cover at least the following overarching dimensions: physical, mental, 
social health  ?ĂƐŝŶĐůƵĚĞĚŝŶt,K ?ƐĚĞĨŝŶŝƚŝŽŶŽĨŚĞĂůƚŚ ?[32], and somatic sensations (e.g. pain) [33].  
The coverage of the 6 measures is shown in Table 4 against a list of physical and psychosocial health 
domains (adapted from [10]).  The measures differ in size with EQ-5D covering the least number of 
domains and AQoL-8D the most.  The vast majority of items in EQ-5D, HUI3 and 15D are concerned 
with physical domains, while SF-6D and particularly AQoL cover more psychosocial and wellbeing 
domains.  QWB-SA is mainly concerned with symptoms or problems and so predominantly covers 
physical aspects (although it covers more mental health aspects than the earlier version of QWB).  
There are notable gaps in many of the measures including cognition in EQ-5D, SF-6D and QWB-SA; 
and sleep in EQ-5D, SF-6D and HUI3. However, care must be taken in using the list in Table 4 since it 
may not be comprehensive, and at the same time the domains are not mutually exclusive, so for 
example family and work activities may be considered to be covered by usual activities. 
Furthermore, even where there appears to be a relevant item analysts should examine the specific 
content of the item to verify whether it seems relevant to the concept they wish to measure (e.g. 
the EQ-5D-5L mobility is concerned with walking but this may not be relevant for use in populations 
with large proportions of wheel chair users). 
 
Construct validity is measured empirically in terms of the extent to which a measure reflects known 
differences between groups, or known group validity (KGV), and correlates with other indicators of 
health, or convergent validity (CV).  For KGV tests based on known group differences this depends on 
the basis for the groupings.  Where there are other self-report measures of dimensions of interest 
(that may not be preference-based), such as scales of mobility or self-care, they can be useful in 
assessing whether the GPBM descriptive system is sensitive to such differences.  In practice, studies 
in the literature often use clinical measures that may have only a weak relationship to health related 
quality of life (HRQoL) , such as visual acuity, respiratory function or symptoms of schizophrenia.  
Great care must be taken to scrutinise the measures being used to establish known group 
differences or convergence and to establish that these are themselves appropriate indicators of 
preferences [34]. A further problem is most published studies use overall preference weighted 
scores and so conflate the measure of health  W namely the description of health  W with general 
population preferences for difference aspects of health. For this reason we would not expect perfect 
correlation between GPBM scores and other measures of health.  
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Responsiveness is related to construct validity and assesses the ability to reflect known changes in 
health.  This too depends on having an appropriate indicator that the health of a patient has 
changed and the direction of change.  Sometimes an instrument is described as being insensitive, 
and this simply means it is not able to reflect differences or changes in a population, or seems to be 
less sensitive compared to another measure (e.g. small standardised differences or changes).  
 
Box 2 Criteria for selecting preference-based measures 
The usual psychometric selection criteria are practicality, reliability and validity, but these need to 
be considered alongside the valuation methods and requirements of different jurisdictions. 
 
Practical: The practicality depends on acceptability to patients and the cost of administration (e.g. in 
terms of time).  All six measures have been found to be practical for self-administration, though 
shorter measures may be easier to include in trials.  
 
Reliability: This is the ability of a measure to reproduce the same values on two separate 
administrations when there has been no change in health.  All the GPBMs achieve similar levels of 
re-test reliability.  
 
Content validity: This is defined as the extent to which the descriptive system covers the different 
dimensions of health of relevance to the patient population.  The shorter measures inevitably 
struggle to achieve this in some populations, such as the absence of cognition in EQ-5D and SF-6D 
making them less valid in dementia.  On the other hand the longer measures suffer from overlap and 
may be more difficult to value.   
 
Construct validity: This is measured empirically in terms of the extent to which a measure reflects 
known differences between groups, or known group validity (KGV), and correlates with other 
indicators of the health, or convergent validity (CV).  There are too few head to head comparisons to 
select one measure over another in many cases.  Evidence suggests that EQ-5D (the three level 
version) is able to detect differences in many populations (despite the shorter size), but there are 
some important exceptions (e.g. vision and hearing).   
 
Responsiveness: This is related to construct validity and assesses the ability of a measure to reflect 
known changes in health.  As for construct validity, GPBMs have been shown to be unresponsive in 
some conditions.   
 
Valuation: It is not possible to prescribe one valuation technique as valid compared to another, but 
most economists have advocated choice-based methods like TTO or SG.  The appropriateness of 
valuation methods depends on the extent to which the technique and source of values meet the 
requirements of the relevant policy maker.  For those requiring choice based methods this would 
rule out 15D, HUI3 and QWB, and some jurisdictions require country specific preference values.   
 
Comparability: Some reimbursement agencies require one particular measure to achieve 
comparability (more on this in the discussion), but may permit submissions using other measures 
where this can be justified. 
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5.2  Review of studies comparing measures 
The literature on the empirical evidence of validity and responsiveness is too large to provide a 
systematic review for this article.  Instead we draw heavily on a recent review of reviews conducted 
across the five measures [30].  The majority of published studies reviewed just one or two measures 
with very few examples of three or more instruments being compared. 
 
Thirty reviews of measures were identified across more than 25 conditions covering several hundred 
studies [30].  However, the vast majority of the evidence was for the three level version of the EQ-5D 
(n = 29 studies), followed by SF-6D (n = 12) and then HUI3 (n = 8), with very little on the AQoL (n = 3) 
or 15D (n = 2), and none for the EQ-5D-5L.  The number of studies in each review varied from 5 to 
22.  This evidence base in part reflects the tendency for more research into the EQ-5D, following the 
publication of NICE ?s preference for EQ-5D in 2008 [11].  This makes it very difficult to make 
statements about the comparative performance across the measures (Box 2).  Furthermore, there is 
considerable variation in the way reviews report evidence.  Only a broad summary of findings is 
given here (for more details see [30]). 
 
Box 3 Evidence on construct validity and responsiveness of EQ-5D  
  
Major areas of concern: 
- Senses of vision and hearing 
- Severe and complex mental health problems 
- Elderly and dementia 
- Infants (age 0-5) 
 
 
 
Problematic conditions: 
- Chronic obstructive airways disease 
- Orthopaedic leg-reconstruction 
- Rehabilitation patients (with musculosketal, cardiovascular or psychosomatic 
disorders)   
 
 
 
Areas where EQ-5D has been shown to perform well (examples): 
- Rheumatoid arthritis 
- Depression 
- Liver disease 
- Some cancers 
- Skin 
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NB: This is based on available evidence  
Source: based on findings from [34,35,36,9]  
 
Whenever evidence is available, it often supports the performance of GPBMs in many conditions, 
with differences and changes usually in the expected direction and often significant.  This includes 
known group differences between patient populations and healthy populations and between 
severity groups of patients.  The GPBMs have been shown to correlate with one another moderately 
and more highly in some cases.  They have also been shown to respond to hypothesised changes in 
health for many conditions.  
 
It is difficult to compare the psychometric performance of the measures, since there are few head to 
head comparisons, but there are a few findings of note (see Box 3): 
x The first concerns situations where the evidence on EQ-5D suggests mixed or poor levels of 
performance. Three areas stand out from the literature: the senses of vision and hearing 
[34], elderly populations with dementia [37] and more severe and complex mental health 
condition like schizophrenia and bipolar disorder [36].  
x There are other areas where EQ-5D has been shown to be problematic: it was found to be 
less responsive in rehabilitation patients than SF-6D [35], chronic obstructive airways disease 
[38] and orthopaedic leg re-construction [39]. 
 
The EQ-5D has been shown to perform satisfactorily in many conditions including rheumatoid 
arthritis, many cancers and depression [36,34], and was found to be more responsive than HUI3  in 
musculoskeletal disease [40], and more responsive than SF-6D in liver disease [41].  However, there 
is insufficient comparative evidence to draw definitive conclusions between the measures.  There 
are huge gaps in the coverage of evidence across conditions and the quality of evidence is often 
poor.  
 
6. Selecting a measure for economic evaluation  
When selecting a measure for clinical trials or other studies such as observational, the 
recommended approach is to select measures that perform best in terms of practicality, reliability, 
validity and responsiveness in the population of interest.  However, selecting a measure for use in 
economic evaluation, whether alongside a clinical trial or in a decision analytic model, raises 
additional concerns.  These include the appropriateness of the techniques of valuation (e.g. TTO 
versus SG) and its source of values (e.g. general public versus patient).  There is a large academic 
literature on the additional concerns, but in practice it depends on the requirements of the agency 
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to which the economic evaluation will be submitted.  At one extreme, there are England and the 
Netherlands who prefer the EQ-5D [12,42].  In most countries, agencies requiring cost-effectiveness 
evidence do not specify one particular measure, though some specify the valuation method (e.g. 
requiring choice-based techniques such as TTO or SG), or the population from whom the preference 
values should come (e.g. a sample of the general population) [1].  In summary: 
 
x For submissions to NICE, the question is whether there is a strong case for arguing the EQ-
5D is not appropriate in terms of content validity or construct validity.  Measures like the 
HUI3 have been used for submissions involving patients with vision loss, but these 
exceptions are rare.  
x For submissions to other agencies, the analyst should select the best measure in terms of 
psychometric criteria that meets their requirements (e.g. valued using a choice-based 
method).  Some agencies do indicate a list of preferred measures to select from and this will 
influence the selection [1].  Where feasible selection of a measure from such a list should 
follow the criteria outlined in Table 4, and the best measure should be the one that is most 
relevant to the population in terms of the domains it covers, and most sensitive to either 
meaningful known group differences or changes over time. 
x Preference weights are not available for all countries and preference measures.  For settings 
that require country specific weights, there may be scope to map onto an alternative 
measure that does have preference weights.   
 
These recommendations do raise the problem of possible conflict between the needs of different 
agencies and the availability of HSUVs on the relevant patient group (e.g. the constraints of running 
international trials).  Should analysts simply adopt the most widely used measure (namely, EQ-5D) to 
maximise comparability with previous studies?  For some conditions this would be sub-optimal in 
terms of validity, so what happens if a researcher decides to use another, more relevant generic (or 
condition specific) preference-based measure?    
 
 
Finally, whichever values are chosen: 
 
x For transparency reasons the modeling report should clearly describe and justify which 
instrument was used and which valuation methods were applied [43]. 
 
 18 
 
 
 
7. New developments 
1) The development of the 5-level version of EQ-5D: in order to address concerns that the original 3-
level version of EQ-5D may have insufficient levels to detect small differences in health and 
suffer from ceiling effects (i.e. too many patients reporting state 11111), the Euroqol group 
extended the number of severity levels to 5.  The 3-ůĞǀĞůƐŽĨ “ŶŽ ?ƐŽŵĞ ?ĂŶĚĞǆƚƌĞŵĞƉƌŽďůĞŵƐ
 ?Žƌ ƵŶĂďůĞ ƚŽ ĚŽ ? ? ŚĂǀĞ ďĞĞŶ ƌĞƉůĂĐĞĚ ǁŝƚŚ ƚŚĞ  ?-ůĞǀĞůƐ ŽĨ  “ŶŽ ?slight, moderate, severe and 
ĞǆƚƌĞŵĞƉƌŽďůĞŵƐ ?ŽƌƵŶĂďůĞƚŽĚŽ ? ? ?ďƵƚƚŚĞƌĞŚĂƐďĞĞŶŶŽƐƵďƐƚĂŶƚŝǀĞĐŚĂŶŐĞƐƚŽƚŚĞǁŽƌĚŝŶŐ
of the dimensions [5].  There is evidence of some reduction in the number at the ceiling, but 
there is little evidence on its psychometric performance.    The number of official country 
specific  preference weights is growing and at the time of writing these were available for 
Canada, Japan, the Netherlands, Spain, the UK, and Uruquay  [44] 
2) The development of bolt-on dimensions for EQ-5D: to address the concerns that EQ-5D misses 
important dimensions of health, some researchers have been developing extra dimensions to 
add to the existing five.  These cover cognition, vision, hearing, sleep and skin disorders and 
others are being developed.  This research is ongoing and no bolt on versions have been 
approved as yet by the EuroQol Group. 
3) The development of value sets for PROMIS: PROMIS is a comprehensive item bank for measuring 
health [65], and research is ongoing to provide utility values for PROMIS to enable the evidence to 
be used to directly generate HSUVs (see for example [66]. 
 
8. Summary 
GPBMs are designed to be used across all conditions or diseases to generate HSUVs for calculating 
QALYs.  There are six GPBM currently in use and these vary in terms of the dimensions they cover, 
their size, methods of valuation, and the HSUV they generate for the same patient.  The selection of 
GPBM for any given study should be based on content validity and literature reviews of empirical 
evidence on construct validity and responsiveness.  These properties are difficult to demonstrate in 
the absence of a gold standard.  Evidence on construct validity and responsiveness is very limited, 
but what there is suggests GPBMs can reflect important differences in the health related quality of 
life associated with many conditions though there are important exceptions (e.g. poor performance 
of EQ-5D in vision, hearing, complex and severe mental health and dementia).  Any choice of 
measure needs to meet the requirements of different jurisdictions for the instrument and methods 
of valuation. 
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